1. Five-Year Clinical Outcomes of the COBRA Polyzene F NanoCoated Coronary Stent System.
- Author
-
Cutlip, Donald E., Jauhar, Rajiv, Meraj, Perwaiz, Garratt, Kirk N., Novack, Victor, Novack, Lena, Maillard, Luc, Erglis, Andrejs, Stoler, Robert, Barakat, Mark, Silber, Sigmund, and PzF SHIELD Trial Investigators
- Subjects
- *
MYOCARDIAL infarction , *DRUG-eluting stents , *CORONARY artery disease , *TREATMENT effectiveness , *MYOCARDIAL infarction complications , *THROMBOSIS , *RESEARCH , *CLINICAL trials , *RESEARCH methodology , *MEDICAL care , *SURGICAL stents , *EVALUATION research , *CARDIOVASCULAR system , *COMPARATIVE studies , *PROSTHESIS design & construction , *DEATH , *LONGITUDINAL method , *DISEASE complications - Abstract
Background/purpose: The COBRA Polyzene F™ NanoCoated Coronary Stent System (PzF coated stent) stent demonstrated favorable clinical outcomes at 9 months but late results have not been reported. We sought to assess the late safety and effectiveness of the PzF coated stent for treatment of de novo coronary artery lesions.Methods: Patients with de novo coronary artery lesions meeting eligibility criteria were enrolled in a non-randomized, prospective clinical trial and followed for 5 years. The primary endpoint was target vessel failure (TVF, cardiac death, myocardial infarction [MI], or clinically-driven target vessel revascularization [TVR]) at 9 months. Secondary endpoints included major adverse clinical events (MACE, cardiac death, MI, or clinically driven TLR), clinically driven target lesion revascularization (TLR) and definite or probable stent thrombosis during 5-year follow-up. Endpoints at 5 years were analyzed as cumulative incidence accounting for competing risk of death.Results: Of 296 enrolled patients, 290 (98%) were evaluable at 5 years. By 5 years, MACE had occurred in 61 (21.3%), cardiac death in 11 (4.2%), MI in 25 (8.6%), and TLR in 34 (12.0%) subjects. Between follow-up years 1 and 5, a first MACE occurred in 17 (6.2%), including 10 (4.0%) cardiac death, 4 (1.6%) MI, and 7 (2.9%) TLR events. There were no definite or probable stent thromboses.Conclusions: The PzF coated stent demonstrated continued safety and effectiveness through 5 years with low to very low incident rates of MACE, MI, TLR and stent thrombosis between 1 and 5 years after stent placement. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF